# Phase 3 disease trials recruiting: 170 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 170 trials in phase 3 for disease that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 disease trials: 170 rows for $8.50, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 5 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/disease

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 170
- Recruiting or not yet: 170
- Read on: November 19, 2026

## Trials

The 25 newest of 170, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07944625 | Clinical Trial to Evaluate the Protective Effect of Larazotide Acetate in Individuals With Well-Controlled Celiac Disease | Interlude Biopharma Co. | Phase 3 | Not yet recruiting | Celiac Disease, Celiac Disease in Adolescents | 414 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07944625) |
| November 12, 2026 | NCT07932314 | Prognostic Value of Oxygen-15 Water PET in Coronary Artery Disease | Vastra Gotaland Region | Phase 3 | Recruiting | Coronary Artery Disease, Microvascular Coronary Artery Disease, Microvascular Coronary Dysfunction | 40,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07932314) |
| November 10, 2026 | NCT07927140 | The Efficacy and Safety of Venglustat Compared With Cerezyme in Pediatric Participants 2 to 11 Years of Age With Gaucher Disease Type 3... | Sanofi | Phase 3 | Not yet recruiting | Gaucher's Disease Type III | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07927140) |
| November 4, 2026 | NCT07917247 | Safety and Efficacy of Secukinumab Versus Mycophenolate Mofetil in Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease | Chinese PLA General Hospital | Phase 3 | Recruiting | Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917247) |
| October 13, 2026 | NCT07872423 | Phase III Trial of VDJ001 In Patients With Idiopathic Multicentric Castleman Disease | Beijing VDJBio Co., LTD. | Phase 3 | Recruiting | Anti IL-6R, Castleman's Disease, Multicentric | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07872423) |
| October 2, 2026 | NCT07854782 | Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Regeneron Pharmaceuticals | Phase 3 | Recruiting | Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD | 1,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07854782) |
| September 29, 2026 | NCT07847411 | Study of Velaglucerase Beta ERT in Children With Gaucher Disease | CANbridge Life Sciences Ltd. | Phase 3 | Not yet recruiting | Gaucher Disease, Gaucher Disease Type 1, Gaucher Disease Type 3 | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07847411) |
| September 22, 2026 | NCT07833514 | Misocholic Tablets for Non-Viral Elevated Liver Enzymes | Hanoi Medical University | Phase 3 | Not yet recruiting | Alcohol-Related Liver Disease, Drug-Induced Liver Injury, Non-alcoholic Fatty Liver Disease | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07833514) |
| September 21, 2026 | NCT07830108 | ACT4RHD is an Open-label, Randomised, Adaptive Platform Trial to Evaluate Novel and Repurposed Clinical Interventions for Patients With... | Starship Child Health, Te Toka Tumai Auckland | Phase 3 | Not yet recruiting | Rheumatic Fever, Rheumatic Heart Disease in Children, Acute Rheumatic Fever, Rheumatic Heart Disease | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07830108) |
| September 17, 2026 | NCT07825402 | A Trial of ONO-2808 in Participants With the Parkinsonian Subtype of Multiple System Atrophy (MSA-P) | Ono Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Multiple System Atrophy, Parkinson Variant | 486 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07825402) |
| September 16, 2026 | NCT07822893 | Effect of Botulinum Toxin on Resting Tremor of the Refractory Upper Limb in Parkinsonians | University Hospital, Toulouse | Phase 3 | Not yet recruiting | PARKINSON DISEASE (Disorder) | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07822893) |
| September 1, 2026 | NCT07798232 | Penicillin to Prevent Early Rheumatic Heart Disease in School-Aged Children | Children's Hospital Medical Center, Cincinnati | Phase 3 | Not yet recruiting | Rheumatic Heart Disease in Children | 9,622 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07798232) |
| August 24, 2026 | NCT07782671 | The NICE-PAD II Trial | Northwestern University | Phase 3 | Not yet recruiting | Peripheral Artery Disease (PAD) | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07782671) |
| August 21, 2026 | NCT07778667 | A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry Disease | Idorsia Pharmaceuticals Ltd. | Phase 3 | Recruiting | Fabry Disease | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07778667) |
| August 17, 2026 | NCT07768891 | Beclometasone Dipropionate and Formoterol Inhalation Aerosol for Asthma | Lunan Better Pharmaceutical Co., LTD. | Phase 3 | Recruiting | Asthma (Diagnosis) | 416 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07768891) |
| August 13, 2026 | NCT07761936 | Safinamide vs Placebo for Pain in Patients With Parkinson's Disease and Motor Fluctuations | Universita di Verona | Phase 3 | Recruiting | PARKINSON DISEASE (Disorder), Pain, Pain Management, Parkinson Disease (PD) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07761936) |
| August 7, 2026 | NCT07753603 | Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED) | Sling Therapeutics, Inc. | Phase 3 | Recruiting | Thyroid Eye Disease, TED, Graves Orbitopathy | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07753603) |
| August 7, 2026 | NCT07752784 | Evaluate the Concordance Between PET Imaging of \[18F\]-APN-1607 Injection and Postmortem Brain Tissue Tau Pathology in Individuals With HV... | JYAMS PET Research & Development Limited | Phase 3 | Recruiting | Alzheimer's Disease | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07752784) |
| August 3, 2026 | NCT07741045 | Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of TJ0113 Capsules in Patients With Early-Onset Parkinson's Disease | Hangzhou PhecdaMed Co., Ltd. | Phase 3 | Recruiting | Parkinson's Disease (PD), Parkinson Disease 6, Early-Onset | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07741045) |
| July 22, 2026 | NCT07719543 | Efficacy and Safety of Lenalidomide in Patients With IgG4-Related Disease | Chinese PLA General Hospital | Phase 3 | Not yet recruiting | Immunoglobulin G4-Related Disease | 146 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07719543) |
| July 21, 2026 | NCT07717411 | A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease | Hoffmann-La Roche | Phase 3 | Recruiting | Alzheimer's Disease | 1,600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07717411) |
| July 9, 2026 | NCT07693777 | A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia | Zhejiang Doer Biologics Co., Ltd. | Phase 3 | Not yet recruiting | Severe Hypertriglyceridemia (sHTG), Hypertriglyceridemia | 480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07693777) |
| July 8, 2026 | NCT07689630 | Anti-CD25 Monoclonal Antibody for Prevention of Acute GVHD After Haploidentical HSCT | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 3 | Recruiting | Graft Versus Host Disease, Hematologic Neoplasms | 186 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07689630) |
| July 7, 2026 | NCT07686055 | Precision Management of Urinary Tract Symptoms in Older Women | Sponsor not shown (see the record) | Phase 3 | Recruiting | Urinary Tract Infection (Diagnosis) | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07686055) |
| June 22, 2026 | NCT07661056 | Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease | Biohaven Therapeutics Ltd. | Phase 3 | Recruiting | Graves Disease | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07661056) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 8 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 6 |
| Assistance Publique - Hôpitaux de Paris | 6 |
| [Takeda](https://specstream.ai/data/clinical-trials/company/takeda) | 6 |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 5 |
| Northwestern University | 4 |
| [Sanofi](https://specstream.ai/data/clinical-trials/company/sanofi) | 4 |
| [Janssen Research & Development, LLC](https://specstream.ai/data/clinical-trials/company/janssen-research-and-development-llc) | 4 |
| University College, London | 3 |
| Weill Medical College of Cornell University | 3 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 3 |
| Children's Hospital Medical Center, Cincinnati | 2 |
| JYAMS PET Research & Development Limited | 2 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 2 |
| Sinotau Pharmaceutical Group | 2 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 2 |
| University Hospital, Toulouse | 2 |
| Xuanwu Hospital, Beijing | 2 |
| [AB Science](https://specstream.ai/data/clinical-trials/company/ab-science) | 2 |
| VA Office of Research and Development | 2 |
| Shanghai Jiao Tong University School of Medicine | 2 |
| Chinese PLA General Hospital | 2 |
| [Sinovac Biotech Co., Ltd](https://specstream.ai/data/clinical-trials/company/sinovac-biotech-co-ltd) | 2 |
| [argenx](https://specstream.ai/data/clinical-trials/company/argenx) | 2 |
| Eidos Therapeutics, a BridgeBio company | 2 |

## By country

| Country | Trials |
| --- | --- |
| United States | 74 |
| China | 47 |
| France | 46 |
| Canada | 43 |
| Spain | 41 |
| United Kingdom | 40 |
| Italy | 40 |
| Poland | 36 |
| Japan | 35 |
| Belgium | 33 |
| Germany | 33 |
| Australia | 30 |
| Netherlands | 30 |
| South Korea | 29 |
| Israel | 27 |
| Brazil | 26 |
| Taiwan | 24 |
| Argentina | 21 |
| Portugal | 20 |
| Czechia | 20 |
| Greece | 17 |
| Hungary | 16 |
| Puerto Rico | 16 |
| Denmark | 15 |
| Bulgaria | 14 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Veterans hospitals in the United States](https://specstream.ai/data/businesses/veterans-hospitals/united-states)
- [Waterproofing contractors in the United States](https://specstream.ai/data/businesses/waterproofing-contractors/united-states)
- [Window installers in the United States](https://specstream.ai/data/businesses/window-installers/united-states)
- [Acupuncture clinics in the United States](https://specstream.ai/data/businesses/acupuncture-clinics/united-states)
- [Allergy and immunology practices in the United States](https://specstream.ai/data/businesses/allergy-and-immunology-practices/united-states)
- [Arabian restaurants in the United States](https://specstream.ai/data/businesses/arabian-restaurants/united-states)
